2/5
05:31 pm
cmmb
Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
Low
Report
Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
2/5
05:31 pm
cmmb
Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
Low
Report
Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
12/2
08:00 am
cmmb
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Medium
Report
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
11/25
01:49 pm
cmmb
Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
08:00 am
cmmb
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Medium
Report
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
11/20
08:00 am
cmmb
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
11/20
06:02 am
cmmb
Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
High
Report
Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.